Search - tctmd.com

Displaying 221 - 240 of 296

Sort: Relevancy | Date

News Daily News

Certain Risk Factors Carry Higher MI Risk in Women Than in Men

Shelley Wood

November 23, 2018

News Daily News

Angina Without Obstructive Stenosis: No Longer a ‘Black Box’ Mystery, Say Experts

Michael O'Riordan

November 23, 2018

News Conference News AHA 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Michael O'Riordan

November 16, 2018

News Opinion Conversations in Cardiology

Conversations in Cardiology: Can a Patient With Tissue Valves Switch From Warfarin to a NOAC?

November 16, 2018

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Conference News VIVA 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

L.A. McKeown

November 15, 2018

News Conference News AHA 2018

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

Caitlin E. Cox

November 13, 2018

News Conference News AHA 2018

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

Shelley Wood

November 11, 2018

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

News Conference News AHA 2018

VITAL: No Benefits to Vitamin D and Omega-3s in Reducing Major CV Events, Cancer

Shelley Wood

November 10, 2018

News Conference News AHA 2018

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

Todd Neale

November 10, 2018

News Daily News

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Michael O'Riordan

November 07, 2018

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

News Daily News

Beta-blocker Use in Pregnancy Doesn’t Up Birth Defect Risk, Study Suggests

Caitlin E. Cox

October 15, 2018

News Conference News TCT 2018

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

Todd Neale

September 24, 2018

News Conference News ESC 2018

Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE

Shelley Wood

August 26, 2018

News Conference News ESC 2018

Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61

Michael O'Riordan

August 26, 2018

News Daily News

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

Michael O'Riordan

August 02, 2018

News Daily News

NOACs Particularly Beneficial for Women With A-fib, Study Suggests

Todd Neale

July 11, 2018

News Daily News

All-Cause Death Not Increased With Febuxostat Among Medicare Patients With Gout

Caitlin E. Cox

June 19, 2018

Advertisement

Certain Risk Factors Carry Higher MI Risk in Women Than in Men

Angina Without Obstructive Stenosis: No Longer a ‘Black Box’ Mystery, Say Experts

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Conversations in Cardiology: Can a Patient With Tissue Valves Switch From Warfarin to a NOAC?

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

VITAL: No Benefits to Vitamin D and Omega-3s in Reducing Major CV Events, Cancer

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Beta-blocker Use in Pregnancy Doesn’t Up Birth Defect Risk, Study Suggests

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE

Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

NOACs Particularly Beneficial for Women With A-fib, Study Suggests

All-Cause Death Not Increased With Febuxostat Among Medicare Patients With Gout

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content